Tolvaptan Use to Treat SIADH in a Child.

Abstract

Hyponatremia is one of the most common electrolyte abnormalities encountered in the clinical setting in hospitalized patients. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the leading cause of hyponatremia in most of these cases. While fluid restriction, hypertonic saline infusion, diuretics, and the treatment of underlying conditions constitute the first line of treatment of SIADH, in refractory cases, and especially for pediatric patients, there seems not to be any other choice for treatment. Tolvaptan, although its use in pediatric patients is still very limited, might be an attractive treatment option for correction of hyponatremia due to SIADH. Here we present a pediatric case of SIADH that was resistant to treatment with fluid restriction and hypertonic saline infusion and was treated successfully with tolvaptan. Tolvaptan could be a good, safe, and effective treatment option in pediatric SIADH cases that are resistant to treatment. However, the dosage should be titrated carefully.

• Authors: Adem Yasin Koksoy, Meltem Kurtul, Aslı Kantar Ozsahin, Fatma Semsa Cayci, Meltem Tayfun, Umut Selda Bayrakci
• Journal: The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG (J Pediatr Pharmacol Ther) 2018 Nov-Dec Vol. 23 Issue 6 Pg. 494-498 ISSN: 1551-6776 [Print] United States
• PMID: 30697137 (Publication Type: Case Reports)